Multiple myeloma (MM) is a complex disease characterized by considerable genetic heterogeneity. The updated NCCN Guidelines for MM have added new “preferred” regimens for transplant and nontransplant candidates, and have moved some formerly “preferred” regimens to the “other” category. Supportive care has improved outcomes for patients, and new treatments in combination have extended survival for patients with MM. Novel agents on the horizon are poised to raise the bar even further.
|Original language||English (US)|
|Number of pages||4|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - May 1 2017|
ASJC Scopus subject areas